Name:	**Jan**
Surname:	**Novotny**
Sex:	Male
D.O.B.:	10th June 1971
Country of citizenship:	Czech Republic
Personal information:	Married

Pregradual education

1985 –1989 High School, Prague, Czech Republic

1989 – 1995 1st Faculty of Medicine, Charles University, Prague

Postgraduate education

1999	**Specialisation exam:**	Radiation oncology
2003	**Disputation:**	Ph.D. degree in Molecular Biology "Detection of K-ras mutations in benign and malignant diseases of the hepatobiliary tract."; 1st Faculty of Medicine, Charles University, Prague
2004	**Specialisation exam:**	Medical Oncology
2011	**Docent**	in the field of Medical Oncology at the 1st Faculty of Medicine, Charles University, Prague

Employment

1995 – 1998, 1999 – 2012	Clinic Oncology, General University Hospital, Prague, Czech Republic
1998 – 1999	Dept. Pediatric Oncology, Motol University Hospital, Prague, Czech Republic
2005 – 2009	Dept. Oncology, Hospital Pribram, Czech Republic Head of the Dept.
2009 – 2010	Dept. Oncology, Inst. Oncology and Rehabilitation Na Plesi, Czech Republic, Head of the Dept.
2010 – 2012	Avicennus s.r.o. (hospitals Kutna Hora and Nymburk), Head of the Dept.
2012 – ongoing	Sunderby sjukhus, Luleå, Sweden, Senior Consultant

Professional interests

Breast cancer
Gastrointestinal tumors
Hereditary cancer syndromes
Tumor genetics
Forensic expert for Oncology and Radiotherapy, Ministery of Justice of the Czech Republic since 2015

Current membership:

European Society for Medical Oncology
American Society of Clinical Oncology
Czech Society for Oncology
Czech Medical Association

Former membership:

Multinational Society on Supportive Care in Cancer

Clinical trials experience:

- **INFORM, MEDIDATA Rave data capture systems**
  (RCT ... randomized clinical trial)

- **Colorectal cancer:**

AMGEN 0763	RCT panitumumab vs cetuximab
AMGEN 0259	RCT FOLFOX (FOLFIRI) + bevacizumab +/- pegfligrastim (trial steering committee member)
POSEIDON	RCT CPT11 + cetuximab +/- EMD 525797
HORIZON II	RCT XELOX / CAPOX +/- cediranib

- **Supportive care in cancer:**

NETU 1029	standard antiemetic treatment vs same treatment with netupitant

- **Breast cancer:**

BAY 12444	capecitabine +/- sorafenib in metastatic breast cancer

Teaching experience:

- Education of medical students,
- Education of physicians while on the training to become Medical Oncologists – Institute for Postgraduate Medical Education lectures and courses
- Mentor for Ph.D. students in the field of Molecular oncology and Tumor biology
- Mentor for dr. Ioannis Gkekas

Follows the list of selected publication with biggest impact that were done as a result of various scientifical research projects sponsored by IGA MZ CR, GA CR, LPR and others; and I activelly participated in these projects.

Publications

A) Monography:

NOVOTNY Jan, VITEK Pavel, PETRUZELKA, Lubos: Clinical and Radiation Oncology. TRITON 2005, Prague, Czech Republic

NOVOTNY Jan, VITEK Pavel: Oncology in Clinical Praxis, 532 pp. MF 2012, Prague, Czech Republic

NOVOTNY Jan, VITEK Pavel, KLEIBL, Zdenek: Oncology in Clinical Praxis, 854 pp. MF 2015, Prague, Czech Republic

Currently is in preparation the manuscript of the 3rd Edition of „Onkologie v klinicke praxi“:



Planned publication date: May 2019

B) Chapter(s) in monographies:

ZAVORAL, Miloslav, et al.: Karcinom pankreatu. GALEN 2005, Prague, Czech Republic

J. Novotny, L. Petruzelka: Onkologická terapie karcinomu pankreatu.

PAVLISTA, David, et al.: Neinvazivní karcinomy prsu. MAXDORF JESSENIUS 2008, Prague, Czech Republic

J. Novotny: Chemoprevence vzniku a recidivy nadoru prsu.

P. Tesarova, J. Novotny: Onkologicka lecba duktalniho karcinomu in situ.

J. Novotny: Identifikace zen se zvysenym rizikem karcinomu prsu.

C) Scientific articles

Breast cancer

Novotny J, Pecen L, Petruzelka L, Svobodnik A, Dusek L, Danes J, Skovajsova M. Breast cancer risk assessment in the Czech female population--an adjustment of the original Gail model. Breast Cancer Res Treat. 2006 Jan;95(1):29-35. Epub 2005 Dec 1. PubMed PMID: 16319995.

Kleibl Z, Novotny J, Bezdickova D, Malik R, Kleiblova P, Foretova L, Petruzelka L, Ilencikova D, Cinek P, Pohlreich P. The CHEK2 c.1100delC germline mutation rarely contributes to breast cancer development in the Czech Republic. Breast Cancer Res Treat. 2005 Mar;90(2):165-7. PubMed PMID: 15803363.

Mateju M, Kleiblova P, Kleibl Z, Janatova M, Soukupova J, Ticha I, Novotny J, Pohlreich P. Germline mutations 657del5 and 643C>T (R215W) in NBN are not likely to be associated with increased risk of breast cancer in Czech women. Breast Cancer Res Treat. 2012 Jun;133(2):809-11. doi: 10.1007/s10549-012-2049-x. Epub 2012 Apr 11. PubMed PMID: 22491912.

Kleibl Z, Havranek O, Kormunda S, Novotny J, Foretova L, Machackova E,Soukupova J, Janatova M, Tavandzis S, Pohlreich P. The AIB1 gene polyglutamine repeat length polymorphism and the risk of breast cancer development. J Cancer Res Clin Oncol. 2011 Feb;137(2):331-8. doi: 10.1007/s00432-010-0889-5. Epub 2010 Apr 27. PubMed PMID: 20422428.

Mateju M, Stribrna J, Zikan M, Kleibl Z, Janatova M, Kormunda S, Novotny J, Soucek P, Petruzelka L, Pohlreich P. Population-based study of BRCA1/2 mutations: family history based criteria identify minority of mutation carriers. Neoplasma. 2010;57(3):280-5. PubMed PMID: 20353281.

Hüttelová R, Kleibl Z, Rezátová J, Krutílková V, Foretová L, Novotný J, Kotlas J, Zikán M, Pohlreich P. [Prerequisites for preimplantation genetic diagnosis (PGD in carriers of mutations responsible for hereditary cancers]. Klin Onkol. 2009;22 Suppl:S69-74. Czech. PubMed PMID: 19764403.

Soucek P, Borovanova T, Pohlreich P, Kleibl Z, Novotny J. Role of single nucleotide polymorphisms and haplotypes in BRCA1 in breast cancer: Czech case-control study. Breast Cancer Res Treat. 2007 Jun;103(2):219-24. Epub 2006 Oct 13. PubMed PMID: 17039264.

Pohlreich P, Zikan M, Stribrna J, Kleibl Z, Janatova M, Kotlas J, Zidovska J, Novotny J, Petruzelka L, Szabo C, Matous B. High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area. Breast Cancer Res. 2005;7(5):R728-36. Epub 2005 Jul 19. PubMed PMID: 16168118; PubMed Central PMCID: PMC1242140.

Janku F, Kleibl Z, Novotny J, Tesarova P, Petruzelka L, Matous B. Mammaglobin A, a novel marker of minimal residual disease in early stages breast cancer. Neoplasma. 2004;51(3):204-8. PubMed PMID: 15254674.

Colorectal cancer

Pardini B, Bermejo JL, Naccarati A, Di Gaetano C, Rosa F, Legrand C, Novotny J, Vodicka P, Kumar R. Inherited variability in a master regulator polymorphism (rs4846126) associates with survival in 5-FU treated colorectal cancer patients. Mutat Res. 2014 Aug-Sep;766-767:7-13. doi: 10.1016/j.mrfmmm.2014.05.007. Epub 2014 Jun 7. PubMed PMID: 25847265.

Pardini B, Rosa F, Naccarati A, Vymetalkova V, Ye Y, Wu X, di Gaetano C, Buchler T, Novotny J, Matullo G, Vodicka P. Polymorphisms in microRNA genes as predictors of clinical outcomes in colorectal cancer patients. Carcinogenesis. 2015 Jan;36(1):82-6. doi: 10.1093/carcin/bgu224. Epub 2014 Nov 3. PubMed PMID: 25368035.

Vymetalkova V, Pardini B, Rosa F, Di Gaetano C, Novotny J, Levy M, Buchler T, Slyskova J, Vodickova L, Naccarati A, Vodicka P. Variations in mismatch repairgenes and colorectal cancer risk and clinical outcome. Mutagenesis. 2014 Apr 22. [Epub ahead of print] PubMed PMID: 24755277.

Huhn S, Bevier M, Pardini B, Naccarati A, Vodickova L, Novotny J, Vodicka P,Hemminki K, Försti A. Colorectal cancer risk and patients' survival: influence of polymorphisms in genes somatically mutated in colorectal tumors. Cancer Causes Control. 2014 Jun;25(6):759-69. doi: 10.1007/s10552-014-0379-1. Epub 2014 Apr 5. PubMed PMID: 24706189.

Pardini B, Rosa F, Barone E, Di Gaetano C, Slyskova J, Novotny J, Levy M, Garritano S, Vodickova L, Buchler T, Gemignani F, Landi S, Vodicka P, NaccaratiA. Variation within 3'-UTRs of base excision repair genes and response to therapyin colorectal cancer patients: A potential modulation of microRNAs binding. ClinCancer Res. 2013 Nov 1;19(21):6044-56. doi: 10.1158/1078-0432.CCR-13-0314. Epub 2013 Sep 13. PubMed PMID: 24036853.

Lu S, Bevier M, Huhn S, Sainz J, Lascorz J, Pardini B, Naccarati A, Vodickova L, Novotny J, Hemminki K, Vodicka P, Försti A. Genetic variants in C-type lectingenes are associated with colorectal cancer susceptibility and clinical outcome.Int J Cancer. 2013 Nov 15;133(10):2325-33. doi: 10.1002/ijc.28251. Epub 2013 May 29. PubMed PMID: 23650115.

Huhn S, Bevier M, Rudolph A, Pardini B, Naccarati A, Hein R, Hoffmeister M,Vodickova L, Novotny J, Brenner H, Chang-Claude J, Hemminki K, Vodicka P, Försti A. Shared ancestral susceptibility to colorectal cancer and other nutritionrelated diseases. BMC Med Genet. 2012 Oct 5;13:94. doi: 10.1186/1471-2350-13-94. PubMed PMID: 23036011; PubMed Central PMCID: PMC3522999.

Naccarati A, Pardini B, Stefano L, Landi D, Slyskova J, Novotny J, Levy M, Polakova V, Lipska L, Vodicka P. Polymorphisms in miRNA-binding sites of nucleotide excision repair genes and colorectal cancer risk. Carcinogenesis. 2012 Jul;33(7):1346-51. doi: 10.1093/carcin/bgs172. Epub 2012 May 11. PubMed PMID: 22581836.

Campa D, Sainz J, Pardini B, Vodickova L, Naccarati A, Rudolph A, Novotny J,Försti A, Buch S, von Schönfels W, Schafmayer C, Völzke H, Hoffmeister M, FrankB, Barale R, Hemminki K, Hampe J, Chang-Claude J, Brenner H, Vodicka P, Canzian F. A comprehensive investigation on common polymorphisms in the MDR1/ABCB1 transporter gene and susceptibility to colorectal cancer. PLoS One.2012;7(3):e32784. doi: 10.1371/journal.pone.0032784. Epub 2012 Mar 2. PubMed PMID: 22396794; PubMed Central PMCID: PMC3292569.

Landi D, Gemignani F, Pardini B, Naccarati A, Garritano S, Vodicka P,Vodickova L, Canzian F, Novotny J, Barale R, Landi S. Identification of candidate genes carrying polymorphisms associated with the risk of colorectal cancer byanalyzing the colorectal mutome and microRNAome. Cancer. 2012 Oct1;118(19):4670-80. doi: 10.1002/cncr.27435. Epub 2012 Jan 26. PubMed PMID:22282400.

Jirásková A, Novotný J, Novotný L, Vodicka P, Pardini B, Naccarati A, Schwertner HA, Hubácek JA, Puncochárová L, Šmerhovský Z, Vítek L. Association of serum bilirubin and promoter variations in HMOX1 and UGT1A1 genes with sporadic

colorectal cancer. Int J Cancer. 2012 Oct 1;131(7):1549-55. doi: 10.1002/ijc.27412. Epub 2012 Feb 18. PubMed PMID: 22212955.

Carrai M, Steinke V, Vodicka P, Pardini B, Rahner N, Holinski-Feder E, Morak M, Schackert HK, Görgens H, Stemmler S, Betz B, Kloor M, Engel C, Büttner R,Naccarati A, Vodickova L, Novotny J, Stein A, Hemminki K, Propping P, Försti A,Canzian F, Barale R, Campa D. Association between TAS2R38 gene polymorphisms and colorectal cancer risk: a case-control study in two independent populations of Caucasian origin. PLoS One. 2011;6(6):e20464. doi: 10.1371/journal.pone.0020464. Epub 2011 Jun 2. PubMed PMID: 21674048; PubMed Central PMCID: PMC3107225.

Huhn S, Ingelfinger D, Bermejo JL, Bevier M, Pardini B, Naccarati A, Steinke V, Rahner N, Holinski-Feder E, Morak M, Schackert HK, Görgens H, Pox CP, Goecke T, Kloor M, Loeffler M, Büttner R, Vodickova L, Novotny J, Demir K, Cruciat CM,Renneberg R, Huber W, Niehrs C, Boutros M, Propping P, Vodièka P, Hemminki K, Försti A. Polymorphisms in CTNNBL1 in relation to colorectal cancer with evolutionary implications. Int J Mol Epidemiol Genet. 2011 Jan 1;2(1):36-50. Epub 2010 Nov 25. PubMed PMID: 21537400; PubMed Central PMCID: PMC3077237.

Pardini B, Kumar R, Naccarati A, Prasad RB, Forsti A, Polakova V, Vodickova L, Novotny J, Hemminki K, Vodicka P. MTHFR and MTRR genotype and haplotypeanalysis and colorectal cancer susceptibility in a case-control study from the Czech Republic. Mutat Res. 2011 Mar 18;721(1):74-80. doi:10.1016/j.mrgentox.2010.12.008. Epub 2011 Jan 4. PubMed PMID: 21211571.

Pardini B, Kumar R, Naccarati A, Novotny J, Prasad RB, Forsti A, Hemminki K, Vodicka P, Lorenzo Bermejo J. 5-Fluorouracil-based chemotherapy for colorectalcancer and

MTHFR/MTRR genotypes. Br J Clin Pharmacol. 2011 Jul;72(1):162-3. Doi: 10.1111/j.1365-2125.2010.03892.x. PubMed PMID: 21204909; PubMed Central PMCID: PMC3141199.

Campa D, Pardini B, Naccarati A, Vodickova L, Novotny J, Steinke V, Rahner N,Holinski-Feder E, Morak M, Schackert HK, Görgens H, Kötting J, Betz B, Kloor M, Engel C, Büttner R, Propping P, Försti A, Hemminki K, Barale R, Vodicka P, Canzian F. Polymorphisms of genes coding for ghrelin and its receptor in relationto colorectal cancer risk: a two-step gene-wide case-control study. BMC Gastroenterol. 2010 Sep 28;10:112. doi: 10.1186/1471-230X-10-112. PubMed PMID: 20920174; PubMed Central PMCID: PMC2954942.

Hlavata I, Vrana D, Smerhovsky Z, Pardini B, Naccarati A, Vodicka P, Novotny J, Mohelnikova-Duchonova B, Soucek P. Association between exposure-relevantpolymorphisms in CYP1B1, EPHX1, NQO1, GSTM1, GSTP1 and GSTT1 and risk of colorectal cancer in a Czech population. Oncol Rep. 2010 Nov;24(5):1347-53. PubMed PMID: 20878130.

Lascorz J, Försti A, Chen B, Buch S, Steinke V, Rahner N, Holinski-Feder E, Morak M, Schackert HK, Görgens H, Schulmann K, Goecke T, Kloor M, Engel C, Büttner R, Kunkel N, Weires M, Hoffmeister M, Pardini B, Naccarati A, Vodickova L, Novotny J, Schreiber S, Krawczak M, Bröring CD, Völzke H, Schafmayer C, Vodicka P, Chang-Claude J, Brenner H, Burwinkel B, Propping P, Hampe J, Hemminki K. Genome-wide association study for colorectal cancer identifies riskpolymorphisms in German familial cases and implicates MAPK signalling pathways in disease susceptibility. Carcinogenesis. 2010 Sep;31(9):1612-9. doi: 10.1093/carcin/bgq146. Epub 2010 Jul 7. PubMed PMID: 20610541.

Campa D, Vodicka P, Pardini B, Naccarati A, Carrai M, Vodickova L, Novotny J, Hemminki K, Försti A, Barale R, Canzian F. A gene-wide investigation on polymorphisms in the taste receptor 2R14 (TAS2R14) and susceptibility to colorectal cancer. BMC Med Genet. 2010 Jun 9;11:88. doi: 10.1186/1471-2350-11-88. PubMed PMID: 20534144; PubMed Central PMCID: PMC2893173.

Pardini B, Naccarati A, Polakova V, Smerhovsky Z, Hlavata I, Soucek P, Novotny J, Vodickova L, Tomanova V, Landi S, Vodicka P. NBN 657del5 heterozygous mutations and colorectal cancer risk in the Czech Republic. Mutat Res. 2009 Jun18;666(1-2):64-7. doi: 10.1016/j.mrfmmm.2009.04.004. Epub 2009 Apr 22. PubMed PMID: 19393249.

Pechlivanis S, Bermejo JL, Pardini B, Naccarati A, Vodickova L, Novotny J, Hemminki K, Vodicka P, Försti A. Genetic variation in adipokine genes and risk of colorectal cancer. Eur J Endocrinol. 2009 Jun;160(6):933-40. doi: 10.1530/EJE-09-0039. Epub 2009 Mar 9. Erratum in: Eur J Endocrinol. 2009Jul;161(1):211. PubMed PMID: 19273568.

Polakova V, Pardini B, Naccarati A, Landi S, Slyskova J, Novotny J, VodickovaL, Bermejo JL, Hanova M, Smerhovsky Z, Tulupova E, Kumar R, Hemminki K, Vodicka P. Genotype and haplotype analysis of cell cycle genes in sporadic colorectal cancer in the Czech Republic. Hum Mutat. 2009 Apr;30(4):661-8. doi:10.1002/humu.20931. PubMed PMID: 19224585.

Kleibl Z, Havranek O, Hlavata I, Novotny J, Sevcik J, Pohlreich P, Soucek P. The CHEK2 gene I157T mutation and other alterations in its proximity increase the risk of sporadic colorectal cancer in the Czech population. Eur J Cancer. 2009 Mar;45(4):618-24. doi: 10.1016/j.ejca.2008.09.022. Epub 2008 Nov 6. PubMed PMID: 18996005.

Tulupova E, Kumar R, Hanova M, Slyskova J, Pardini B, Polakova V, Naccarati A, Vodickova L, Novotny J, Halamkova J, Hemminki K, Vodicka P. Do polymorphismsand haplotypes of mismatch repair genes modulate risk of sporadic colorectal cancer? Mutat Res. 2008 Dec 15;648(1-2):40-5. doi: 10.1016/j.mrfmmm.2008.09.005. Epub 2008 Sep 21. PubMed PMID: 18851982.

Campa D, Pardini B, Naccarati A, Vodickova L, Novotny J, Försti A, Hemminki K, Barale R, Vodicka P, Canzian F. A gene-wide investigation on polymorphisms inthe ABCG2/BRCP transporter and susceptibility to colorectal cancer. Mutat Res. 2008 Oct 14;645(1-2):56-60. doi: 10.1016/j.mrfmmm.2008.08.001. Epub 2008 Aug 19. PubMed PMID: 18775442.

Campa D, Vodicka P, Pardini B, Novotny J, Försti A, Hemminki K, Barale R, Canzian F. Could polymorphisms in ATP-binding cassette C3/multidrug resistance associated protein 3 (ABCC3/MRP3) modify colorectal cancer risk? Eur J Cancer. 2008 Apr;44(6):854-7. doi: 10.1016/j.ejca.2008.02.004. Epub 2008 Mar 7. PubMed PMID: 18313914.

Landi D, Gemignani F, Naccarati A, Pardini B, Vodicka P, Vodickova L, Novotny J, Försti A, Hemminki K, Canzian F, Landi S. Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer. Carcinogenesis. 2008 Mar;29(3):579-84. doi: 10.1093/carcin/bgm304. Epub 2008 Jan 12. PubMed PMID:18192692.

Pardini B, Naccarati A, Novotny J, Smerhovsky Z, Vodickova L, Polakova V,Hanova M, Slyskova J, Tulupova E, Kumar R, Bortlik M, Barale R, Hemminki K, Vodicka P. DNA repair genetic polymorphisms and risk of colorectal cancer in the Czech Republic. Mutat Res. 2008 Feb 1;638(1-2):146-53. Epub 2007 Oct 2. PubMed PMID: 17991492.

Pechlivanis S, Pardini B, Bermejo JL, Wagner K, Naccarati A, Vodickova L, Novotny J, Hemminki K, Vodicka P, Försti A. Insulin pathway related genes andrisk of colorectal cancer: INSR promoter polymorphism shows a protective effect. Endocr Relat Cancer. 2007 Sep;14(3):733-40. PubMed PMID: 17914103.

Farmacogenetics

Fidlerova J, Kleiblova P, Kormunda S, Novotny J, Kleibl Z. Contribution of the β-ureidopropionase (UPB1) gene alterations to the development of fluoropyrimidine-related toxicity. Pharmacol Rep. 2012;64(5):1234-42. PubMed PMID: 23238479.

Fidlerova J, Kleiblova P, Bilek M, Kormunda S, Formankova Z, Novotny J, Kleibl Z. Contribution of dihydropyrimidinase gene alterations to the development of serious toxicity in fluoropyrimidine-treated cancer patients. Cancer Chemother Pharmacol. 2010 Mar;65(4):661-9. doi: 10.1007/s00280-009-1071-0. Epub 2009 Aug 1.PubMed PMID: 19649633.

Kleibl Z, Fidlerova J, Kleiblova P, Kormunda S, Bilek M, Bouskova K, Sevcik J, Novotny J. Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy. Neoplasma. 2009;56(4):303-16. PubMed PMID: 19473056.

Ticha I, Kleiblova P, Fidlerova J, Novotny J, Pohlreich P, Kleibl Z. Lack of large intragenic rearrangements in dihydropyrimidine dehydrogenase (DPYD) gene influoropyrimidine-treated patients with high-grade toxicity. Cancer Chemother Pharmacol. 2009 Aug;64(3):615-8. doi: 10.1007/s00280-009-0970-4. Epub 2009 Mar 14. PubMed PMID: 19288105.